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However, these values are not familiar for Clinicians. The aim of
this study was to introduce a patient specific and clinically appli-
cable biomechanical rupture risk assessment tool that would be
easy for Vascular Surgeons to comprehend.
Methods: Clinical data(gender, age, Smoking, chronic
obstructive lung disease, mean arterial pressure, family his-
tory) and CT images were retrospectively gathered from
200(142male, 44 female) non ruptured AAA patients from 4
different hospitals in Sweden, Belgium and Germany. FE
models were created using the diagnostics system A4 Clinics
(VASCOPS, Austria) and the maximum diameter, PWS and
PWRR was calculated automatically. Statistical analysis was
performed with Mathematica (Wolfram Research Inc, USA).
Results: The maximum diameter was normally distrib-
uted in males and females and no difference was found be-
tween PWS levels in men and women (P  .091) but the
PWRR was higher in women (P .005). PWS increased in a
linear fashion and PWRR exponentially with diameter. We
then relatedPWRRto themaximumdiameters of patients and
calcuated the Rupture Risk Equvialent diameter (RRED) as
shown in the figure. A PWRR of 0.48 corresponds to an
RRED of 55 millimeters.
Conclusions: Biomechanical AAA rupture risk assess-
ment integrates risk based on clinical parameters and data
from CT images. The RRED expresses this information as
a diameter that is comprehensible for clinicians.
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Objectives:The FDA is collaborating with clinicians to
characterize human aortic anatomy in a population-based
study, CHAP, to increase patient eligibility for EVAR and
augment endograft (EVG) design and evaluation.
Methods: Preoperative CT scans from three centers
were prospectively entered into a database from 7/96 to
8/10. A blinded third-party, M2S, recorded 25 standard-
ized measurements from the 3D reconstructions. For in-
clusion, AAA had to be infrarenal and 5 cm, or 4-5 cm if
the orthogonal sac diameter was more than twice the
normal aortic diameter. The anatomic criteria were ana-
lyzed in 1108 men and 357 women with untreated AAA.
Results: Anatomy of men and women with AAA is
significantly different in each age category (P.005) except
for neck length and angulation in the youngest group*.
The aortic neck shortens and becomesmore angulated with
age (P.005), especially for women. Other differences
between men and women are more consistent by age
group.
Conclusions: Almost all the key anatomic parameters
are significantly different between men and women. Some
anatomic differences are independent of age, but the dis-
parity in neck length, angulation and access becomes more
apparent as patients age, with women having more severe
anatomy at all ages. All of these factors lower EVAR eligi-
bility for older patients, especially women, with only 29% of
women over 80 years eligible for EVAR based on current
EVG’s Instructions for Use.
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Table. Mean (and 10th-90th percentile range) anatomic parameters by gender and age
Years
Women Men
 69 70–79  80  69 70–79  80
Neck diameters, mm 24 20–29 24 18–34 24 19–30 26 21–33 26 21–32 26 21–32
Neck length, mm 17* 4–32 14 4–31 13 3–30 19* 5–35 17 4–35 18 5–39
Angle, deg 38* 17–58 46 27–74 50 27–64 35* 18–57 38 18–61 41 19–65
Ao bifurcation diameter, mm 20 12–28 19 12–30 19 13–27 24 15–35 22 15–33 22 15–32
Min com iliac diameter, mm 11 7–15 11 8–14 11 8–15 14 10–19 14 11–19 12 11–15
Ave ext iliac diameter, mm 6 5–8 7 5–9 7 5–8 8 7–10 9 7–11 9 7–11
Min iliac access, mm 5 3–7 5 4–7 5 4–7 7 6–9 7 6–10 8 5–10
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Objectives: To evaluate the role of intraoperative an-
eurysm sac embolization during EVAR (edEVAR) with
coils and glue, in the prevention of Endoleak type II (ET2).
Methods: Two groups were compared: 85 patients under-
went standard EVAR during 2007-2008 (Group A) and 81
patients underwent edEVARduring2009-2010 (GroupB).CT
scans were elaborated with the Osirix 4.0 software in order to
obtain aneurysm sac volume. ET2 rates at the first CT scan
follow-up, as mid-term free from ET2 and free from related
reintervention were compared. Preoperative patent number of
aortic side branches (IMA, lumbars, accessories renal), thrombus
and sac volume were evaluated for their association with ET2 in
the two groups, using multivariate analysis.
Results: Patients characteristics, Society for Vascular
Surgery (SVS) comorbidity score (0.850.44 vs
0.820.48; P  .68) and operative time (185.451.8 vs
172.950.8;P .99) were similar between group A and B.
The first CT scan (or  2 months) demonstrated signif-
icantly higher number of ET2 in group A compared to
group B (23.5% vs 9.8%;P  .02). Spontaneous ET2 reso-
lution occurred in 65% of patients in Group A and 79% in
group B (P  1.0), while sac volume increased in 25% vs
10% (P .63) of cases respectively. At 18 months (range:6
to 24) overall mean difference in sac volume shrinkage
(27.212.3 cm3 vs 24.811.6 cm3; P  .19) and free
from ET2 (91.8% vs 96.3%; P  0.33) were similar, while
free from reintervention was significantly lower in Group A
(94.1% vs 98.8%; P  .05) compared to Group B. Multi-
variate analysis showed preoperative aneurysm sac volume
 125 cm3 to be the only independent significant predictor
of ET2 (OR, 3.64; 95% CI, 1.54 to 8.58; P  .003).
Conclusions:EdEVAR seems to be a valid approach to
prevent ET2 and its complications during short and mid-
term follow-up. Patients with preoperative aneurysm sac
volume higher than 125 cm3 should be considered for a
more aggressive intraoperative embolization.
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Objectives: Alvimopan is a peripherally acting mu-opioid
antagonist used to shorten the time to return of gastrointestinal
function after surgery. Randomized clinical trials have demon-
strated a shorter time period to return of bowel function and
discharge in open abdominal colonic surgeries, but nodata exists
on its use in the aortic vascular surgery population.
Methods: Alvimopan was administered to patients hav-
ing open abdominal aortic aneurysm repair or aortofemoral
bypass. The administration protocol was one 12 mg dose
preoperatively and doses of 12mg twice a day postoperatively
until the first bowel movement or a total of seven days. There
were seven patients in the study group and 6 patients in the
control group. The primary end points were time to regain
bowel function and length of hospital stay.
Results: The average age (Study  69.3  3.8 years vs.
Control 68.5 3.4 years; P  .88), abdominal aortic aneu-
rysm size (Study 5.9 0.3 cm vs. Control 5.3 0.5 cm;P
 .28), procedure time (Study2.10.1 hours vs. Control
2.6 0.3 hours;P .12), gender and comorbidities were not
different between the two cohorts. There is a quicker time to
regain bowel function (Study 2.9 0.4 days vs. Control
4.5  0.6 days; P  .04) and shorter hospitalization (Study
5.60.3days vs.Control6.80.4days;P .03) in the
study group compared to the control group.
Conclusions: These preliminary data show that peri-
operative Alvimopan benefits patients, resulting in quicker
time to regain bowel function and shorter hospitalization,
consistent with previous studies involving open abdominal
bowel resection. This improved resource utilization sup-
ports further investigation via a large scale randomized
pharmacoeconomic endpoint trial.
Author Disclosures: W. M. Bogey: Nothing to disclose;
M. B. Burruss: Nothing to disclose; T. W. Capps: Noth-
ing to disclose; B. A. Ehlert: Nothing to disclose; F. M.
Parker: Nothing to disclose; C. S. Powell: Nothing to
disclose; M. C. Stoner: Nothing to disclose.
PS12.
Open Repair of Aortic Coarctation in Adults
KristoferM. Charlton-Ouw,Maria E. Codreanu, Samuel S.
Leake, Harleen K. Sandhu, Daniel Calderon, Ali Azizza-
deh, Anthony L. Estrera, Hazim J. Safi. Dept. of Cardio-
thoracic and Vascular Surgery, University of Texas at
Houston Medical School, Houston, TX
Objectives: Aortic coarctation is one of themost common
congenital aortic lesionsand isusually repaired inearlychildhood.
Without correction, death often occurs before the fourth decade
and surviving adults suffer from hypertension and other compli-
cations from poor distal flow.We report on our experience with
open repair of aortic coarctation in adults.
Methods:We retrospectively reviewed all patients age16
years requiring open repair (de novo and redo) of aortic coarcta-
tion.Ourprotocol for spinal cordprotection includesdistal aortic
perfusionvia atriofemoral bypass,moderatepassivehypothermia,
and cerebrospinal fluid drainage. Indications for repair, operative
details, and outcomes were analyzed.
Results: Between 1999 and 2011, we treated 30 patients
withadult aortic coarctation.Themedianagewas40years (range
17-69) and there were 16 males. Eight patients had previous
repair with recurrence; 22 patients had native coarctation. Aortic
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